Drofen Machinery validates 160-pen-per-minute insulin assembly line

By AI, Created 4:35 PM UTC, May 18, 2026, /AGP/ – Drofen Machinery says it completed factory acceptance testing for a high-speed insulin pen assembly line built to run at 160 pieces per minute. The milestone is aimed at CDMOs and drugmakers under pressure to scale diabetes and GLP-1 production while meeting strict compliance requirements.

Why it matters: - Diabetes and GLP-1 drug demand is pushing manufacturers to expand injectable production faster. - CDMOs face added pressure to scale while keeping assembly, compliance and validation aligned. - A validated turnkey line can reduce vendor handoffs and speed time to market for critical therapies.

What happened: - Drofen Machinery completed factory acceptance testing for a high-speed insulin pen assembly line. - The line is designed to operate at 160 pieces per minute. - The company said the system is aimed at global CDMOs and pharmaceutical manufacturers. - Managing Director Jordan Xu said the milestone reflects Drofen Machinery’s push to deliver an end-to-end production and validation setup.

The details: - The validated line covers both pre-assembly and final assembly. - The system integrates mechanical components and drug cartridges. - Drofen Machinery positions its model as a single-source turnkey offering rather than a multi-vendor setup. - The package includes the equipment, the injection pens, and regulatory validation support. - The assembly line is built with data integrity controls aligned with 21 CFR Part 11. - The project also follows GAMP5 guidelines. - Drofen Machinery says the setup is designed to help pharmaceutical companies navigate global approval requirements. - Xu said the bundled device, automation and validation framework is intended to remove interface risks that can slow scale-ups.

Between the lines: - The announcement signals a broader shift toward integrated manufacturing partnerships in injectable drugs. - For CDMOs, a single-source model can lower coordination burden and reduce delays caused by mismatched equipment, documentation or validation work. - The compliance references also suggest Drofen Machinery is targeting buyers that need equipment ready for regulated markets, not just high-speed output.

What’s next: - Drofen Machinery is likely to use the validated line as a proof point for more CDMO and pharmaceutical contracts. - The company will compete on speed, compliance support and turnkey delivery as injectable and GLP-1 capacity expands. - End users still need to complete their own implementation and market-specific approval steps before commercial use.

The bottom line: - Drofen Machinery is betting that high-speed assembly is not enough on its own; the winning offer for injectable drugmakers is speed plus validation plus compliance support.